Prismaccess / Evalumade, online global platforms, provide comprehensive overviews and specific country regulations and guidelines on HTA and reimbursement.
Dedicated to market access and pricing departments and covering 27 regulation agencies worldwide, our platforms allow our clients to anticipate their market access positioning and enter the market based on the most appropriate data.
Updated in real time, Prismaccess / Evalumade analyze HTA & reimbursement decisions, structuring key data in an easy-to-use format, allowing users to detect trends and gain insight into their own and competitor products.
We are integrating AI and Machine learning to enhance the capabilities of our platforms.
Forecasts and screenings, accelerated search in hundreds of documents, real-time response to a given problem, extraction and analysis, our data will be processed with increased power.
The reimbursement policy of health authorities is becoming more restrictive with the increased number of innovative drugs introduced on the market.
With a fast process of large volumes of data, Prioritis is able to deliver deep analysis on specific criteria, essential for a successful assessment.
The key inputs managed by AI:
Our database covers all therapeutic areas from major HTA countries and is monitored and updated on a daily basis by our HTA experts.
Access immediately to key information to incorporate into your product or disease area landscape.
Search can be made by drug name, active ingredient, manufacturer, type of recommendation, therapeutic area. Our interface has been specifically built to facilitate downloads, data extraction and printing.
Evalumade, an interface dedicated to market access leaders, offers clear top-level visual information about HTA decisions, allowing users to detect trends and gain insight into their own and competitor products.